03.02.26 -- A Biotech Business Model That's Investor-Friendly

To keep pace with surging GLP-1 demand, pharma needs partners that can rapidly scale injectable production while maintaining flexibility, quality, and regulatory rigor.

The top five common cell line development pitfalls — scalability, stability, complexity, analytics, and tech transfer — can be avoided with experienced partners and integrated, predictive strategies.

Review a semi-automated method for dynamically assessing plunger migration under controlled variations in temperature and pressure, utilizing computer vision tools.

Understand how elite CDMO project management acts as a conductor—integrating molecule expertise, rigorous readiness, and disciplined GMP execution to drive biologics manufacturing.

Scale-out biomanufacturing enhances flexibility, speeds timelines, lowers risk, and enables efficient parallel production for scalable, resilient biologics and advanced therapies.

See three flexible Optima fill‑finish and syringe assembly systems to boost performance, accuracy, and scalability, enabling efficient processing of diverse formats and supporting rapid CDMO growth.

Explore strategies for accommodating the ever-increasing upstream titers and volumes to prevent downstream purification from becoming a bottleneck.

To safeguard the consistent delivery of essential therapies to patients around the world, biopharmaceutical companies, alongside their CDMO partners, are rethinking traditional supply models.